Bio Essence (BIOE) Cash from Discontinued Operations (2023 - 2024)

Bio Essence (BIOE) recorded quarterly Cash from Discontinued Operations of 120825.0 in Q4 2024, up 188.34% quarter-over-quarter from 136777.0 in Q1 2024, and down 79.01% on a YoY basis from 575766.0 in Q1 2024.

Bio Essence (BIOE) Cash from Discontinued Operations (2023 - 2024) Analysis & Trends

Bio Essence's Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 120825.0 for Q4 2024.

  • In Q4 2024, Cash from Discontinued Operations fell 79.01% year-over-year to 120825.0; the TTM figure through Dec 2024 stood at 15952.0 (up 63.92% YoY), while the FY2024 annual figure was 15952.0, up 63.92% from the prior year.
  • Cash from Discontinued Operations was 120825.0 for Q4 2024 at Bio Essence, up from 136777.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 575766.0 in Q4 2023 to a low of 267981.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn -
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -
10 Bio Essence - - 319,353.00 -

Historic Data

Download Data
DateValue
Dec 31, 2024 120,825.00
Dec 31, 2024 120,825.00
Mar 31, 2024 -136,777.00
Mar 31, 2024 -136,777.00
Dec 31, 2023 575,766.00
Dec 31, 2023 575,766.00
Sep 30, 2023 -267,981.00
Sep 30, 2023 -267,981.00
Jun 30, 2023 -155,221.00
Jun 30, 2023 -155,221.00
Mar 31, 2023 -196,778.00
Mar 31, 2023 -196,778.00